Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Joshua Reed
  • Venkateswarlu KanamarlapudiEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101966


Historical Background

In 1906, it was first identified that the pancreas could be stimulated by factors from the gut to aid in removal of nutrients, and porcine small intestinal extract was used to treat diabetic patients (Graaf et al. 2016). In 1928, it was demonstrated that injection of secretin extracted from the small intestinal mucosa displays a hypoglycemic effect that is mediated through the pancreas (Creutzfeldt 2005). In the 1960s, it was shown that orally administered glucose induces a much stronger insulin response than that induced by intravenously administered glucose, despite the similar resulting plasma glucose levels – this was termed the “incretin effect” (Creutzfeldt 2005; Graaf et al. 2016). Gastric inhibitory peptide (GIP) was the first incretin hormone to be discovered in 1975, which is produced by K cells of the small intestine (Creutzfeldt 2005). It was then observed in 1981...

This is a preview of subscription content, log in to check access.


  1. Ahlkvist L, Vikman J, Pacini G, Ahrén B. Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. Regul Pept. 2012;178:29–35.  https://doi.org/10.1016/j.regpep.2012.06.004.CrossRefPubMedGoogle Scholar
  2. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 2004;17:183–90.  https://doi.org/10.2337/diaspect.17.3.183.CrossRefGoogle Scholar
  3. Brissova M, Shiota M, Nicholson W, Gannon M, Knobel S, Piston D, et al. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem. 2002;277:11225–32.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein–coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. 2002;8:179–88.PubMedCrossRefPubMedCentralGoogle Scholar
  5. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept. 2005;128:87–91.  https://doi.org/10.1016/j.regpep.2004.08.004.CrossRefPubMedGoogle Scholar
  6. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013;24:85–91.  https://doi.org/10.1016/j.tem.2012.11.008.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Donath MY, Burcelin R. GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes Care. 2013;36:S145–S8.  https://doi.org/10.2337/dcS13-2015.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Goldstein BJ, Wieland DM. Type 2 diabetes: principles and practice. 2nd ed. New York: Informa Healthcare; 2007.Google Scholar
  9. Graaf C, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, et al. Glucagon-like peptide-1 and its Class B G protein–coupled receptors: a long march to therapeutic successes. Pharmacol Rev. 2016;68:954–1013.  https://doi.org/10.1124/pr.115.011395.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.  https://doi.org/10.1152/physrev.00034.2006.CrossRefPubMedGoogle Scholar
  11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.  https://doi.org/10.1124/pr.108.000604.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes. 2010;59:1117–25.  https://doi.org/10.2337/db09-1899.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15:15–27.  https://doi.org/10.1111/j.1463-1326.2012.01663.x.CrossRefPubMedGoogle Scholar
  14. Padidela R, Patterson M, Sharief N, Ghatei M, Hussain K. Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. Eur J Endocrinol. 2009;160:53–8.  https://doi.org/10.1530/eje-08-0807.CrossRefPubMedGoogle Scholar
  15. Salehi M, Aulinger B, D’Alessio DA. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes. 2012;61:2728–33.  https://doi.org/10.2337/db11-1825.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Sharma R, McDonald TS, Eng H, Limberakis C, Stevens BD, Patel S, et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)–derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos. 2013;41:2148–57.  https://doi.org/10.1124/dmd.113.054254.CrossRefPubMedGoogle Scholar
  17. Shields DWT, Roth SE, Brenner MJ. Cell-free synthesis and processing of multiple precursors to glucagon. Nature. 1981;289:511–4.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Thompson A, Kanamarlapudi V. Type 2 diabetes mellitus and glucagon like peptide-1 receptor signalling. Clin Exp Pharmacol. 2013;3.  https://doi.org/10.4172/2161-1459.1000138.
  19. Voet D, Voet JG. Biochemistry. 4th ed. New York: Wiley; 2011.Google Scholar
  20. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis – roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci. 2009;122:893–903.  https://doi.org/10.1242/jcs.034355.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Wang X, Liu H, Chen J, Li Y, Qu S. Multiple factors related to the secretion of glucagon-like peptide-1. Int J Endocrinol. 2015;2015:651757.  https://doi.org/10.1155/2015/651757.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Institute of Life Science 1, School of MedicineSwansea UniversitySwanseaUK